DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection
zlk20251119
Phase 1 other active
Quick answer
DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection for DC-CIK Treatment is a Phase 1 program (other) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- DC-CIK Treatment
- Phase
- Phase 1
- Modality
- other
- Status
- active